BioProspect is one of Australia’s emerging natural compound and product development companies that is conducting research and early-stage commercialisation in the pesticide and agricultural sectors.

ASX / Media Announcements

July 2010

Appendix 4C 30 June 2010

Dispute with Solagran Limited

Development Agreement with Solagran Limited

June 2010

Termilone trials update

Development Agreement with Solagran Limited

Resignation of Director and Appendix 3Z

Appendix 3Y Change of Director's interest notice

2010 SPP results and Appendix 3B

GI-GUARD horse treatment submitted for regulatory approval

Results of General Meeting

General meeting presentation

May 2010

Agripro natural animal health products update

Update on Re Gen Wellness Products

Share Purchase Plan extension to 11 June

Termilone commercialisation update

Share Purchase Plan Issue Price and Terms

Share Purchase Plan clarification

Article - Australian Forest & Timber – Keeping termites at bay, naturally

Article - BiotechnologyNews – BioProspect boosts natural therapies range

Article - Pest Control Technology – Termilone on track for commercialisation

Sky News Business TV interview – Peter May

April 2010
Share Placement & Appendix 3B

Notice of General Meeting

Share Purchase Plan announcement

Appendix 4C 31 March 2010

Termilone CSIRO trial results

Article - Australian Life Scientist – BioProspect keeps the termites at bay

March 2010
Bionews March 2010 issue

Expiry of Listed Options

Successful horse safety studies

Appendix 3B

Article - Business Acumen Queensland – Natural ‘killer’ Qcide wins IP sale

February 2010
Half year reports and accounts

BioProspect and Solagran  agree to commercialise

APVMA approval for Termilone

Article - BiotechnologyNews – Termite oil gets the tick

January 2010
Appendix 4C 31 Dec 2009

Capital placement and Appendix 3B

Qcide Intellectual Property agreement

December 2009
Ensystex market development agreement
November 2009
Appointment of COO

AGM Results of meeting

AGM presentation slides

Appointment of Managing Director

October 2009
Appendix 4C 30 Sept 09

Appendix 3Y Change of Director's interests

Notice of AGM and Proxy Form

Annual Report to Shareholders

October issue of Bionews

September 2009
Appendix 3X

Audited accounts y/e 30 June 2009

Board Appointment

Appendix 3X

Appendix 3B

August 2009
Board Appointment

Appendix 4E & preliminary results y/e June 2009

BioProspect concludes Re-Gen acquisition

July 2009
Appendix 4c 30 June 2009

Agreement to acquire Re-Gen Wellness Products

Major safety study on horses with Bioeffective A

Termilone registration update with APVMA

May 2009
HOA to purchase Re-Gen Wellness Products
April 2009
Appendix 4C 31 March 2009

Response to ASX query

Final Director's Notice Appendix 3Z

Mr Peter Stedwell

March 2009
March issue of Bionews
February 2009
Appendix 4D & Half-year accounts
January 2009
Appendix 4C 31 Dec 2008
Ensystex evaluation agreement
November 2008
Final director's interest notice S Morrow
Final director's interest notice P Landau
AGM results
AGM CEO's presentation
Director Resignations
Termilone reg'n lodged with APVMA
October 2008
Appendix 4C 30 Sept 08
Chairman's letter and Notice of AGM
2008 AAnnual Report
Update on Sect 249D Notice of requisition for GM
Australian patent granted for Termilone
Section 249D Notice of requisition for GM
September 2008
Appointment of CEO
Final Director's Interest Notice
Board changes
Section 249D notice withdrawn
August 2008
Appendix 4E and preliminary final report
Completion of sale of ANZ securities
Poultry trial results-Bioeffectives
EGUS trial results -Bioeffectives
Inhalation toxicity results Termilone
Section 249D notice of requisition for GM
July 2008
Appendix 4C 30 June 2008
June 2008
Resignation of Managing Director 25 June
Qcide licence agreement-Bio-Gene  24 June
Termilone video script by MD 6 June
May 2008
Termilone 28 day dermal toxicity results 1 May
April 2008
Takeovers Panel decision 28 April
Appendix 4C 31 March
Bioeffectives screening trial Dubai 24 April
TERMILONE bioassay result 8 April
ANZ substantial holder notice 7 April
Takeovers Panel response4 April
Takeovers Application 3 April
ASX response 3 April
March 2008
Change of Director interests WD
Change of Director interests PL
February 2008
Appendix 3B 28 Feb
Half year accounts and App 4D
January 2008
Appendix 4C 31 December 2007
Change of Director interests MQ
Change of Director interests SM
Change of Director interests PL
December 2007
Interview with MD by Investor TV
Appendix 3B 7 Dec
Termilone Toxicity Results
November 2007
Appendix 3B 15 Nov
BioProspect Change of Share Registrars
BioProspect AGM commentary for shareholders
BioProspect AGM Presentation 5th Nov
AGM results 5 Nov
Appendix 3B 1 Nov
October 2007
Appendix 4C 30 Sept
Change of address 11 Oct
Letter to shareholders 5 Oct
AGM Notice of Meeting and Proxy Form 5 Oct
2007 Annual Report
August 2007
Appendix 4E & Preliminary annual report
Solagran Licence Agreement signed
Solagran Licence Agreement signed-media release
July 2007
Appendix 4C 30 June 2007
Top 20 option holders and Appendix 3B
Completion of underwriting and Appendix 3B
Change of Director's Interest Notice 16 July
June 2007
Option Underwriting Agreement 18 June
Initial Director's Interest Notice 18 June
Chairman Appointment 18 June
General Meeting Results 8 June
May 2007
Initial Director's Interest Notice 31 May
Final Director's Interest Notice 31 May
Board Changes 31 May
Options Expiry Notice 29 May
Solagran due diligence complete 29 May
Notice of meeting 8 June
April 2007
Appendix 4C March qtr
Initial Director's Interest Notice
Final Director's Interest Notice
Heads of Agreement with Solagran Limited
February 2007
Toxicity test results-Termilone
Appendix 4D and half-year accounts
Completion of placement
Appendix 3B
Capital Raising
January 2007
31 Dec 2006 quarterly report and Appendix 4C
Response to ASX Price Query
November 2006
AGM Poll Results 29 November
AGM General Manager's presentation
ENSIS/CSIRO Agreement
Response to ASX Price Query
October 2006
Appendix 4C 30 September
Field trial update
September 2006
Notice of Annual General Meeting
Appendix 4E & Annual Report 30 June 2006
July 2006
Appendix 4C 30 June 2006
May 2006
Appendix 4C 31 March 2006
April 2006
Executive Appointment
March 2006
ASX Price Query
Appendix 4D Half Yearly Report and Accounts 31 December 2005
February 2006
AP778 Field trial update
January 2006
Quarterly Report 31 December 2005 and Appendix 4C
Expiry of 25 January 2006 Options
Despatch of Prospectus